Literature DB >> 28864608

Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview.

Ken Herrmann1,2, Steven M Larson3, Wolfgang A Weber3.   

Abstract

Mesh：

Year:  2017        PMID： 28864608     DOI： 10.2967/jnumed.117.199570

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  11 in total

1.  First steps in an uncharted territory by WFNMB.

Authors:  Dong Soo Lee; Patricia Bernal Trujillo; Savvas Frangos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02       Impact factor: 9.236

2.  Radiotheranostic Targeting Cancer Stem Cells in Human Colorectal Cancer Xenografts.

Authors:  Xianliang She; Saimei Qin; Boping Jing; Xueyan Jin; Xun Sun; Xiaoli Lan; Rui An
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

3.  Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.

Authors:  Bobby Shaygan; Katherine Zukotynski; François Bénard; Cynthia Ménard; Joda Kuk; Golmehr Sistani; Glenn Bauman; Patrick Veit-Haibach; Ur Metser
Journal:  Can Urol Assoc J       Date:  2021-06       Impact factor: 1.862

Review 4.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

Review 5.  Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Authors:  Maria I Del Olmo-García; Stefan Prado-Wohlwend; Pilar Bello; Angel Segura; Juan F Merino-Torres
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

6.  Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?

Authors:  Sue-Jane Wang; Anthony Fotenos; Shane C Masters; Louis Marzella
Journal:  Theranostics       Date:  2022-03-28       Impact factor: 11.600

Review 7.  Individualization of Radionuclide Therapies: Challenges and Prospects.

Authors:  Hanna Piwowarska-Bilska; Sara Kurkowska; Bozena Birkenfeld
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

8.  The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.

Authors:  Nusrat J Begum; Gerhard Glatting; Hans-Jürgen Wester; Matthias Eiber; Ambros J Beer; Peter Kletting
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

Review 9.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

10.  SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).

Authors:  A González Del Alba; M J Méndez-Vidal; S Vazquez; E Castro; M A Climent; E Gallardo; E Gonzalez-Billalabeitia; D Lorente; J P Maroto; J A Arranz
Journal:  Clin Transl Oncol       Date:  2021-02-24       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.